Will Eli Lilly (LLY) Q3 Mounjaro sales be above __?
$11.07Bmedian
$8B$14B
Median $11.07BMiddle half $10.31B – $11.82B
Install
Will Eli Lilly (LLY) Q3 Zepbound sales be above __?
The odds
$5.44Bmedian
$4B$7B
Median $5.44BMiddle half $5.09B – $5.89B
How the odds have moved
Median: $5.53B on Oct 20, $5.44B now.
The median the market implied over time and its middle half (the band), read from every strike's prices on Polymarket.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Traded |
|---|---|---|---|---|---|---|
| $4.5B | 82% | ▼ 2 | 76¢ | 87¢ | $1.15 | $477 |
| $5B | 82% | ▲ 1 | 67¢ | 97¢ | $1.03 | $576 |
| $5.5B | 46% | ▼ 3 | 36¢ | 56¢ | $1.79 | $1.1K |
| $6B | 19% | ▼ 1 | 3¢ | 35¢ | $2.86 | $566 |
| $6.5B | 17% | ▲ 2 | 3¢ | 30¢ | $3.33 | $592 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: Eli Lilly, Zepbound
Search ›-
Eli Lilly declares $1.73 dividendEli Lilly declares a $1.73 quarterly dividend, with key record and payment dates for income investors. - Payable Dec. 10; for shareholders of record Nov. 13; ex-div Nov. 13. More on Eli Lilly -
Eli Lilly Joins Moonwalk’s $70M Series B RoundMoonwalk Biosciences said it will use the funds to advance its lead candidate for obesity, MW101, into clinical testing by late 2027. Eli Lilly Joins Moonwalkâs $70M Series B Round to Fund Cardiometabolic RNAi Drugs NEW YORK â Moonwalk… -
Eli Lilly (NYSE: LLY) Earnings On October 29 Put A $1.135 Trillion Bet On Two Blockbuster Drugs To The TestBy David Prior | Oct 26, 2026 | Economy & Business, Featured, News & Analysis A pharmaceutical giant valued at roughly $1.135 trillion, Eli Lilly (NYSE: LLY) heads into its October 29 third-quarter earnings report with an uncomfortably… -
Eli Lilly and Company $LLY Stock Holdings Raised by XXI Wealth LLCPosted by Kim Johansen on Oct 26th, 2026 Check Out Our Latest Analysis on LLY Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical… - US judge lets Eli Lilly continue ads for weight-loss drugs, rules against Novo NordiskOct 26 (Reuters) - A U.S. court on Monday allowed Eli Lilly to continue weight-loss drug advertisements that rival Novo Nordisk claimed were false and misleading. (Reporting by Jonathan Stempel in New York)... US judge…
-
Eli Lilly (LLY) Stock: Olomorasib Shows 62% Response Rate in Lung Cancer DataEli Lilly (LLY) shared new lung cancer data on Sunday. The company presented results for its experimental drug olomorasib at the 2026 European Society for Medical Oncology congress in Madrid. The release did not include a stock price move… - US judge won’t block Eli Lilly ads for weight-loss drugs, rules against Novo NordiskOct 26 (Reuters) – A US judge on Monday rejected Novo Nordisk’s request to block Eli Lilly from continuing weight-loss drug advertisements that the Danish drugmaker considered false and misleading. Novo Nordisk had requested a…
- Eli Lilly (LLY) Stock: Lung Cancer Drug Olomorasib Posts 62% Response Rate at ESMOEli Lilly (LLY) put fresh lung cancer data on the table Sunday at the European Society for Medical Oncology congress in Madrid. The focus was olomorasib, its experimental KRAS G12C inhibitor. Eli Lilly and Company, LLY One study tested the…
-
Eli Lilly Says Olomorasib Shows 'Durable Efficacy' in Non-Small Cell Lung Cancer StudiesEli Lilly (LLY) said new trial data showed olomorasib delivered durable first-line activity in patients with KRAS 12. Results from a phase 1/2 study and a phase 3 study showed olomorasib combined with ... Oops, something went wrong U.S… - Eli Lilly Stock Gets a Lift as New Lung Cancer Data Raises HopesEli Lilly (NYSE:LLY) shares climbed nearly 1% in pre-market trading after clinical data showed its experimental drug olomorasib shrank tumors in 62% of patients when paired with immunotherapy and chemotherapy for an aggressive form of lung…
-
Eli Lilly (LLY) Reports Strong Phase 1 Ovarian Cancer DataEli Lilly (NYSE: LLY) reported new Phase 1 data for Sofe-M plus bevacizumab in platinum-sensitive ovarian cancer patients. The regimen showed a high confirmed response rate and disease control rate in both PARP inhibitor-experienced and…
Related markets
All companies ›Largest Company end of October 2026?
92%NVIDIA
- NVIDIA92%▲ 11
- Apple7%▼ 10
- Alphabet<1%
6 more
- Tesla<1%
- Saudi Aramco<1%
- Broadcom<1%
- Microsoft<1%
- Amazon<1%
- SpaceX<1%
The Cheesecake Factory comparable restaurant sales in Q3 (comparable restaurant sales in Q3 2026)
11.35%median
3%12.5%
Median 11.35%
Lowe's customer transactions in Q3 2026
182.85Mhigh with an even chance
Traders see an even chance of trading as high as 182.85M.
- Reaches 178.00M98%
- Reaches 179.00M97%
Largest Company end of December 2026?
65%NVIDIA
- NVIDIA65%▲ 1
- Apple33%
- Alphabet2%
5 more
- Microsoft<1%
- SpaceX<1%
- Tesla<1%
- Saudi Aramco<1%
- Amazon<1%
Another critical Cloudflare incident by...?
99%October 31
- October 3199%▲ 1
- November 3099%▲ 1
- December 3199%▲ 14
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Conservative. Prices read from the venues 5 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Conservative, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Conservative index; prices of stocks, rates and coins from 4Conservative Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions